{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:31:16Z","timestamp":1772166676782,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dexrazoxane is used to treat extravascular leakage of anthracycline antitumor agents, but its own extravascular leakage and management remain underreported. This case aimed to highlight both doxorubicin and dexrazoxane leakage during treatment for diffuse large B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 55-year-old man with diffuse large B-cell lymphoma developed doxorubicin leakage during rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP) therapy, which was treated with dexrazoxane. Subsequently, dexrazoxane leakage occurred, causing erythema and swelling. Topical clobetasol propionate was applied, leading to symptom resolution without necrosis. The patient successfully completed chemotherapy and achieved long-term remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report is one of the first to document the management of dexrazoxane extravascular leakage using topical steroids, effectively preventing severe outcomes. The findings suggest that topical steroids may be a desirable treatment approach for dexrazoxane leakage. Prompt intervention and interdisciplinary care contributed to the favorable outcome. This case highlights the need for further research and guideline refinement to optimize the management of inflammatory extravascular leakage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00446-1","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:09:55Z","timestamp":1749697795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extravascular leakage of dexrazoxane that occurred in a patient with diffuse large B-cell lymphoma: a case report"],"prefix":"10.1186","volume":"11","author":[{"given":"Nao","family":"Wakamiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Isezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohkan","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"446_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60:255\u201366.","journal-title":"Semin Hematol"},{"key":"446_CR2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"The World Health Organization classification of malignant lymphomas in Japan","year":"2000","unstructured":"The World Health Organization classification of malignant lymphomas in Japan. Incidence of recently recognized entities. Lymphoma study group of Japanese pathologists. Lymphoma study group of Japanese pathologists. Pathol Int. 2000;50:696\u2013702.","journal-title":"Pathol Int"},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12185-019-02681-3","volume":"110","author":"K Ohmachi","year":"2019","unstructured":"Ohmachi K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5-diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). Int J Hematol. 2019;110:131\u201346.","journal-title":"Int J Hematol"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0268-960X(90)90015-K","volume":"4","author":"RT Dorr","year":"1990","unstructured":"Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev. 1990;4:41\u201360.","journal-title":"Blood Rev"},{"key":"446_CR5","first-page":"3","volume":"34","author":"M Cassagnol","year":"2009","unstructured":"Cassagnol M, McBride A. Management of chemotherapy extravasations. US Pharm. 2009;34:3\u201311.","journal-title":"US Pharm"},{"key":"446_CR6","first-page":"2410","volume":"41","author":"RF Cox","year":"1984","unstructured":"Cox RF. Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm. 1984;41:2410\u20134.","journal-title":"Am J Hosp Pharm"},{"key":"446_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00006534-197904000-00003","volume":"63","author":"DW Luedke","year":"1979","unstructured":"Luedke DW, Kennedy PS, Rietschel RL. Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plast Reconstr Surg. 1979;63:463\u20135.","journal-title":"Plast Reconstr Surg"},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.soncn.2007.05.003","volume":"23","author":"L Schulmeister","year":"2007","unstructured":"Schulmeister L. Extravasation management. Semin Oncol Nurs. 2007;23:184\u201390.","journal-title":"Semin Oncol Nurs"},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1524-4725.1990.tb00073.x","volume":"16","author":"NB Tsavaris","year":"1990","unstructured":"Tsavaris NB, Karagiaouris P, Tzannou I, Komitsopoulou P, Bacoyiannis C, Karabellis A, et al. Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg Oncol. 1990;16:519\u201322.","journal-title":"J Dermatol Surg Oncol"},{"key":"446_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/BF00686305","volume":"30","author":"NB Tsavaris","year":"1992","unstructured":"Tsavaris NB, Komitsopoulou P, Karagiaouris P, Loukatou P, Tzannou I, Mylonakis N, et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol. 1992;30:330\u20133.","journal-title":"Cancer Chemother Pharmacol"},{"key":"446_CR11","volume-title":"Manidhar Reddy Lekkala","author":"Chiamaka","year":"2024","unstructured":"Chiamaka, Eneh. Manidhar Reddy Lekkala. Jan: Dexrazoxane. StatPearls Publishing; 2024."},{"key":"446_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/tera.1420110114","volume":"11","author":"DI Duke","year":"1975","unstructured":"Duke DI. Prenatal effects of the cancer chemotherapeutic drug ICRF 159 in mice, rats, and rabbits. Teratology. 1975;11:119\u201326.","journal-title":"Teratology"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"key":"446_CR14","first-page":"357","volume":"6","author":"W Seppo","year":"2014","unstructured":"Seppo W. Langer. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 2014;6:357\u201363.","journal-title":"Cancer Manag Res"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5306\/wjco.v7.i1.87","volume":"10","author":"FY Kreidieh","year":"2016","unstructured":"Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016;10:87\u201397.","journal-title":"World J Clin Oncol"},{"key":"446_CR16","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","volume":"91","author":"JO RoCA","year":"1994","unstructured":"RoCA JO, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A. 1994;91:1781\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","volume":"23","author":"JP Fidalgo","year":"2012","unstructured":"Fidalgo JP, Fabregat LG, Cervantes A, Margulies A, Vidall C, Roila F, ESMO Guidelines Working Group. ESMO guideline working group. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. Ann Oncol. 2012;23:vii167\u201373.","journal-title":"Ann Oncol"},{"key":"446_CR18","doi-asserted-by":"publisher","first-page":"103932","DOI":"10.1016\/j.esmoop.2024.103932","volume":"9","author":"K Matsumoto","year":"2024","unstructured":"Matsumoto K, Ryushima Y, Sato J, Aizawa Y, Aoyama T, Akaishi Y, et al. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. ESMO Open. 2024;9:103932.","journal-title":"ESMO Open"},{"key":"446_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00280-021-04280-8","volume":"88","author":"J Nedomansky","year":"2021","unstructured":"Nedomansky J, Haslik W, Pluschnig U, Kornauth C, Deutschmann C, Hacker S, et al. Tissue distribution of epirubicin after severe extravasation in humans. Cancer Chemother Pharmacol. 2021;88:203\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"446_CR20","first-page":"57","volume":"8","author":"M Takagi","year":"2017","unstructured":"Takagi M, Kohama M, Takeuchi M. Experience in the treatment of forearm skin necrosis caused by extravasation leakage of epirubicin. Jpn J Surg Wound Care. 2017;8:57\u201360.","journal-title":"Jpn J Surg Wound Care"},{"key":"446_CR21","first-page":"1462","volume":"58","author":"Y Nakagawa","year":"2016","unstructured":"Nakagawa Y, Kaneko E, Morita H. A case of extravascular leakage of an anticancer drug treated with dexrazoxane. Rinsho Derma (Tokyo). 2016;58:1462\u20133.","journal-title":"Rinsho Derma (Tokyo)"},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.4103\/0973-1482.77081","volume":"6","author":"PA Arroyo","year":"2010","unstructured":"Arroyo PA, Perez RU, Feijoo MA, Hernandez MA. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation. J Cancer Res Ther. 2010;6:573\u20134.","journal-title":"J Cancer Res Ther"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1345\/aph.1M636","volume":"44","author":"AM Tyson","year":"2010","unstructured":"Tyson AM, Gay WE. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation. Ann Pharmacother. 2010;44:922\u20135.","journal-title":"Ann Pharmacother"},{"key":"446_CR24","first-page":"2517","volume":"43","author":"S Kawamoto","year":"2016","unstructured":"Kawamoto S, Shirahata T, Katori T, Izumo T, Kadono H, Fujita H, et al. Effectiveness of dexrazoxane for extravasation of anthracycline antitumor antibiotics - reporting measures developed against extravasation in the hospital. Gan Kagaku Ryoho. 2016;43:2517\u201321.","journal-title":"Gan Kagaku Ryoho"},{"key":"446_CR25","first-page":"467","volume":"50","author":"T Takahata","year":"2023","unstructured":"Takahata T. Four cases who experienced extravasation of anthracyclines and had dexrazoxane therapy. Cancer Chemother. 2023;50:467\u201371.","journal-title":"Cancer Chemother"},{"key":"446_CR26","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.21873\/anticanres.13070","volume":"38","author":"G Howell","year":"2018","unstructured":"Howell G, Oliai C, Schiller G. Liposomal cytarabine-daunorubicin (CPX-351) extravasation: case report and literature review. Anticancer Res. 2018;38:6927\u201330.","journal-title":"Anticancer Res"},{"key":"446_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"446_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2169\/internalmedicine.9329-17","volume":"57","author":"H Okuda","year":"2018","unstructured":"Okuda H, Masatsugu A, Sijimaya T, Arai R. Skin necrosis due to the extravasation of irritant anticancer agents. Intern Med. 2018;57:757\u201360.","journal-title":"Intern Med"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00446-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00446-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:09:57Z","timestamp":1749697797000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00446-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00446-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5987269\/v1","asserted-by":"object"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case has been reported with the approval of the Clinical Research Review Committee of Kameda General Hospital (Permission No.: Case 23\u2009\u2212\u2009015). This case was reported after written consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Verbal and written informed consent was obtained from the patient to publish this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}